Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib.

Ikeda K, Harada-Shirado K, Matsumoto H, Noji H, Ogawa K, Takeishi Y.

J Clin Oncol. 2016 May 10;34(14):e130-3. doi: 10.1200/JCO.2013.51.1188. Epub 2014 Apr 21. No abstract available.

PMID:
24752059
2.

Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.

Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.

Cancer Genet Cytogenet. 2010 May;199(1):56-61. doi: 10.1016/j.cancergencyto.2010.01.018.

PMID:
20417871
3.

Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.

Ferri CA, Bianchini M, Bengió RM, Moiraghi EB, Gonzalez MS, Noriega MF, Larripa IB.

Eur J Haematol. 2015 Mar;94(3):270-2. doi: 10.1111/ejh.12358. Epub 2014 May 13.

PMID:
24766374
4.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

6.

Variant e19a2 BCR-ABL1 fusion transcript in typical chronic myeloid leukemia.

Tutulan-Cunita AC, Chirieac SM, Mocanu G, Luca C, Costache M, Lungeanu A, Arghir A.

Clin Lab. 2011;57(9-10):785-8. Erratum in: Clin Lab. 2011;57(11-12):1041-2.

PMID:
22029197
7.

BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.

Neuendorff NR, Schwarz M, Hemmati P, Türkmen S, Bommer C, Burmeister T, Dörken B, le Coutre P, Arnold R, Westermann J.

Acta Haematol. 2015;133(2):237-41. doi: 10.1159/000368176. Epub 2014 Nov 12.

PMID:
25401297
8.

E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.

Li C, Wang Y, Xu D, Zhang P, Ding X, Zhang N, Xiao M, Huang L, Meng L.

Clin Lab. 2015;61(1-2):183-6.

PMID:
25807654
9.

A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib.

Cea M, Cirmena G, Garuti A, Rocco I, Palermo C, Cagnetta A, Moran E, Colombo N, Grasso R, Fugazza G, Gobbi M, Nencioni A, Ballestrero A, Patrone F.

Leuk Res. 2010 Sep;34(9):e240-2. doi: 10.1016/j.leukres.2010.03.036. Epub 2010 May 5. No abstract available.

PMID:
20447687
10.

Effectiveness of dasatinib in accelerated-phase chronic myeloid leukemia with p190 BCR-ABL1 and a second Philadelphia chromosome.

Rabenau KE, Dolan M, Yohe S, Ustun C.

Cancer Genet. 2014 Mar;207(3):109-10. doi: 10.1016/j.cancergen.2014.02.006. Epub 2014 Feb 22. No abstract available.

PMID:
24703333
11.

First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.

Andrikovics H, Nahajevszky S, Szilvási A, Bors A, Adám E, Kozma A, Kajtár B, Barta A, Poros A, Tordai A.

Hematol Oncol. 2007 Sep;25(3):143-7.

PMID:
17530620
12.

Molecular response to nilotinib in a patient with imatinib-intolerant e19a2-positive chronic myeloid leukemia.

Kajiguchi T, Okuno S, Ohno T, Abe A.

Intern Med. 2014;53(24):2801-4. Epub 2014 Dec 15.

13.

Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?

Rumpold H, Webersinke G.

Curr Cancer Drug Targets. 2011 Jan;11(1):3-19. Review.

PMID:
21062244
14.

A unique BCR-ABL1 transcript with the insertion of intronic sequence from BCR and ABL1 genes in a patient with Philadelphia-positive chronic myeloid leukemia: a case study.

Sadia H, Siddiqui RT, Nasim A.

Cancer Genet Cytogenet. 2010 Aug;201(1):57-61. doi: 10.1016/j.cancergencyto.2010.03.017.

PMID:
20633771
15.

Cytogenetic, fluorescence in situ hybridization, and genomic array characterization of chronic myeloid leukemia with cryptic BCR-ABL1 fusions.

Shao L, Miller S, Keller-Ramey J, Zhang Y, Roulston D.

Cancer Genet. 2015 Jul-Aug;208(7-8):396-403. doi: 10.1016/j.cancergen.2015.04.006. Epub 2015 Apr 25.

PMID:
26186983
16.

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients.

Osman EA, Hamad K, Elmula IM, Ibrahim ME.

Genet Mol Biol. 2010 Apr;33(2):229-31. doi: 10.1590/S1415-47572010005000037. Epub 2010 Jun 1.

17.

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph+ ALL receiving dasatinib.

Olsson-Strömberg U, Hermansson M, Lundán T, Ohm AC, Engdahl I, Höglund M, Simonsson B, Porkka K, Barbany G.

Eur J Haematol. 2010 Nov;85(5):399-404. doi: 10.1111/j.1600-0609.2010.01506.x.

PMID:
20659155
18.

Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.

Foroni L, Gerrard G, Nna E, Khorashad JS, Stevens D, Swale B, Milojkovic D, Reid A, Goldman J, Marin D.

Am J Hematol. 2009 Aug;84(8):517-22. doi: 10.1002/ajh.21457. Review.

19.

High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.

Pelz AF, Kröning H, Franke A, Wieacker P, Stumm M.

Ann Hematol. 2002 Mar;81(3):147-53. Epub 2002 Feb 23.

PMID:
11904740
20.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Kim SH, Menon H, Jootar S, Saikia T, Kwak JY, Sohn SK, Park JS, Jeong SH, Kim HJ, Kim YK, Oh SJ, Kim H, Zang DY, Chung JS, Shin HJ, Do YR, Kim JA, Kim DY, Choi CW, Park S, Park HL, Lee GY, Cho DJ, Shin JS, Kim DW.

Haematologica. 2014 Jul;99(7):1191-6. doi: 10.3324/haematol.2013.096776. Epub 2014 Apr 4.

Supplemental Content

Support Center